Regado Biosciences to Present at the BIO-Europe Conference 2009 on November 3, 2009

Regado Biosciences to Present at the BIO-Europe Conference 2009 on November 3,
2009

BASKING RIDGE, N.J., Oct. 27 /PRNewswire/ -- Regado Biosciences, a privately
held company leading the development of antithrombotic aptamers with active
control agents, announced today that David J. Mazzo, Ph.D., President and
Chief Executive Officer, will be presenting at the BIO-Europe Conference 2009
at the Messe Wien Exhibition & Congress Center in Vienna, Austria. Dr.
Mazzo's presentation will be on Tuesday, November 3, 2009 at 8:45 am (GMT
+1hr) and will include an overview of the Company's pipeline with emphasis on
the lead development program, the anticoagulant system, REG1. This conference
is Europe's largest partnering conference, serving the global biotechnology
industry. The conference attracts leading business development executives
from biotech, pharmaceutical, and finance as well as the most exciting
emerging companies.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the
creation and development of two-component drug systems. Each system comprises
a nuclease-stabilized RNA aptamer that can be controlled directly by its
specific and complementary oligonucleotide active control agent. This
technology is being applied to injectable antithrombotics, including
anticoagulants and antiplatelet agents, a multi-billion dollar market in need
of therapeutics with improved safety profiles and a greater degree of
therapeutic control. Regado's technology is designed to give physicians the
ability to actively and directly control each system's therapeutic effect
providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two
parenteral agents both administered by IV bolus, the first being a potent
highly selective Factor IXa inhibitor (RB006) and the second being its
complementary active control agent (RB007). RB007 can be used to selectively
completely or partially reverse the anticoagulant effect of RB006. REG1 is
intended for application in arterial thrombosis applications, initially in
Acute Coronary Syndrome patients undergoing Percutaneous Coronary
Intervention. REG2, Regado's second product candidate, consists of a
subcutaneously administered formulation of RB006 paired with the IV bolus
formulation of RB007. REG2 is intended for use in venous thrombosis
indications.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are
single stranded oligonucleotides that adopt a specific conformation enabling
direct, specific inhibition of the targeted protein. A key unique feature of
aptamers derives from the fact that they are formed from nucleic acids. As
such, their pharmacologic activity can be controlled by a matched,
complementary oligonucleotide active control agent (the Watson-Crick base pair
complement of a fraction of the agent to be controlled), which can bind to the
aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.

SOURCE Regado Biosciences

Ellen McDonald, Chief Business Officer, Regado Biosciences, +1-908-580-2113,
emcdonald@regadobio.com